Jane Street Group LLC Invests $2.83 Million in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Jane Street Group LLC acquired a new stake in Centessa Pharmaceuticals plc (NASDAQ:CNTA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 177,260 shares of the company’s stock, valued at approximately $2,834,000.

Several other large investors have also bought and sold shares of the stock. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Centessa Pharmaceuticals by 47.7% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC boosted its holdings in Centessa Pharmaceuticals by 103.1% in the third quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock valued at $48,000 after acquiring an additional 1,509 shares during the last quarter. Quarry LP increased its position in Centessa Pharmaceuticals by 47.8% during the 2nd quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after purchasing an additional 3,108 shares during the period. Sandia Investment Management LP bought a new position in Centessa Pharmaceuticals during the 2nd quarter worth approximately $90,000. Finally, Fred Alger Management LLC acquired a new position in shares of Centessa Pharmaceuticals in the 2nd quarter worth approximately $99,000. 82.01% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on CNTA shares. B. Riley began coverage on shares of Centessa Pharmaceuticals in a research report on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective for the company. Guggenheim lifted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Jefferies Financial Group upped their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, September 11th. Morgan Stanley upgraded Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $11.00 to $26.00 in a report on Thursday, September 19th. Finally, BMO Capital Markets increased their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the stock an “outperform” rating in a report on Monday, September 16th. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and a consensus target price of $25.83.

Centessa Pharmaceuticals Stock Down 2.2 %

CNTA stock opened at $17.16 on Friday. The company has a debt-to-equity ratio of 0.15, a quick ratio of 21.52 and a current ratio of 21.52. Centessa Pharmaceuticals plc has a fifty-two week low of $6.65 and a fifty-two week high of $18.97. The stock’s 50 day simple moving average is $16.64 and its 200 day simple moving average is $13.57. The company has a market cap of $2.26 billion, a P/E ratio of -11.22 and a beta of 1.52.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.05. On average, research analysts expect that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CTO Tia L. Bush sold 17,813 shares of the stock in a transaction on Tuesday, December 17th. The stock was sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the transaction, the chief technology officer now owns 147,615 shares in the company, valued at approximately $2,657,070. This represents a 10.77 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Saurabh Saha sold 1,671 shares of the firm’s stock in a transaction that occurred on Friday, November 22nd. The stock was sold at an average price of $18.24, for a total transaction of $30,479.04. Following the completion of the transaction, the chief executive officer now directly owns 575,661 shares of the company’s stock, valued at approximately $10,500,056.64. This trade represents a 0.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 374,642 shares of company stock valued at $6,425,926. Corporate insiders own 11.59% of the company’s stock.

About Centessa Pharmaceuticals

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.